{
  "abstract": "Objectives To determine what drives participation in clinical trials with decentralised elements and to estimate trial participation probabilities for trials with different degrees of decentralisation.Design Patient preference study using a discrete choice experiment.Setting Recruitment in primary, secondary, tertiary care and other settings in the Netherlands (NL), Austria (AT) and Germany (DE).Participants People with type 2 diabetes mellitus (T2DM) aged ≥18 years. A total of 787 people (NL n=276, AT n=265, DE n=246) participated in the study.Main outcome measures Preferences for participation in clinical trials with different options for location and type of contact with the study team, activities to perform by participant, use of digital technologies by participant, number of scheduled contacts, trial duration, known safety and efficacy of the drug.Results How much was known about the safety and efficacy of the drug was the most important element in the decision whether to participate in a clinical trial in all countries. The trial duration, location and type of contact with the study team, and number of scheduled contacts were other important elements. Participation probabilities for hypothetical trial scenarios differed between countries, with the highest rates for a decentralised trial involving video contact (NL: 89%; AT: 99%; DE: 84%).Conclusions People with T2DM prefer to take part in clinical trials with decentralised approaches. Information on preferences can help trialists and protocol developers to design and plan future trials that integrate patients’ needs and thus reduce barriers to participation.",
  "authors": [
    {
      "affiliations": [
        "Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands"
      ],
      "name": "Julia Kopanz"
    },
    {
      "affiliations": [
        "Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands"
      ],
      "name": "Bart Lagerwaard"
    },
    {
      "affiliations": [
        "Erasmus School of Health Policy & Management (ESHPM), Erasmus University Rotterdam, Rotterdam, The Netherlands",
        "Erasmus Choice Modelling Centre, Erasmus University Rotterdam, Rotterdam, The Netherlands"
      ],
      "name": "Jorien Veldwijk"
    },
    {
      "affiliations": [
        "Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria"
      ],
      "name": "Julia K Mader"
    },
    {
      "affiliations": [
        "MVZ Diabeteszentrum Dr. Tews GmbH, Gelnhausen, Germany"
      ],
      "name": "Dietrich Tews"
    },
    {
      "affiliations": [
        "Department of Vascular Medicine and Endocrinology, University Medical Center Utrecht, Utrecht, The Netherlands"
      ],
      "name": "Thomas T van Sloten"
    },
    {
      "affiliations": [
        "Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands"
      ],
      "name": "Diederick E Grobbee"
    },
    {
      "affiliations": [
        "Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands"
      ],
      "name": "Mira G P Zuidgeest"
    },
    {
      "affiliations": [],
      "name": "on behalf of the Trials@Home consortium"
    }
  ],
  "title": "Do people prefer to take part in a clinical trial from home or come to site? A discrete choice experiment in type 2 diabetes mellitus",
  "uid": "23b35321-d6a2-5898-b311-0cc019ad10d5"
}